3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
2
Phase NA
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
3
Conditions
Breast Neoplasms
10
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Hemorrhage
2
Chronic Pain
2
Agnosia
2
Vulvodynia
1
Uterine Cervical Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Radiodermatitis
1
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Interventions
Dacarbazine
25
Nivolumab
24
pembrolizumab
19
Ipilimumab
18
Interferon-alpha
10
trametinib
8
Vemurafenib
8
dabrafenib
7
aldesleukin
7
Temozolomide
7
Introns
7
Interferon alpha-2
6
Interleukin-2
5
Cisplatin
5
Chemotherapy, Adjuvant
5
talimogene laherparepvec
4
cemiplimab
4
binimetinib
4
Radiotherapy
4
Paclitaxel
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
sargramostim
3
encorafenib
3
cobimetinib
3
Vinblastine
3
Surgical Procedures, Operative
3
Specimen Handling
3
Sodium Chloride
3
Radiosurgery
3
Opdualag
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Melanoma
×
Sodium Chloride
×
Clear all
NCT05899465
2025-03-18
PRIME
University of Aarhus
Phase 3
Recruiting
1,204 enrolled
NCT03233828
2024-07-24
IL-2
Nova Scotia Health Authority
Phase 3
Terminated
1 enrolled
3 charts
NCT00518895
2011-11-07
AGENDA
Genta Incorporated
Phase 3
Completed
300 enrolled